The technique at the center of the study is oral contrast-enhanced transabdominal ultrasound, abbreviated OCTU. Conventional transabdominal ultrasound of the stomach has long been hampered by a fundamental physics problem: air in the gastric lumen reflects sound waves almost completely, obscuring the wall beneath. By asking patients to swallow an oral contrast agent that fills and distends the stomach, the examiners eliminate the air barrier and create an acoustic window through which the layered architecture of the gastric wall becomes visible. Under these conditions, the normal stomach wall resolves into five distinct echogenic bands, labeled L1 through L5, corresponding histologically to the mucosal surface, the deep mucosa, the submucosa, the muscularis propria, and the serosa. Tumor depth can then be judged by observing which of these layers a lesion has thickened, disrupted, or breached.

What has limited OCTU in practice is subjectivity. Different ultrasonographers, looking at the same five-layer pattern, have historically disagreed about whether a tumor is confined to the submucosa or has invaded the muscle layer. The Beijing team, led by Yu-Hui Liu, He-Wen Tang, Kun Yan, and Ying Dai, set out to replace impression with measurement. Between December 2023 and December 2024, they prospectively enrolled 150 patients with histologically confirmed gastric cancer who underwent OCTU followed by surgical resection, allowing the ultrasound findings to be checked against the gold standard of pathology. The cohort was divided into a training set of 116 patients, used to derive diagnostic thresholds, and an independent testing set of 34 patients, used to validate them. Two blinded ultrasonographers independently reviewed all images, and the study itself was registered with the Chinese Clinical Trial Registry before enrollment began.

The first practical question was whether the technique could even see the tumors. OCTU visualized the lesion in 144 of the 150 patients, a 96 percent detection rate. The six failures were instructive: five were T1a tumors, the earliest category, in which cancer remains confined to the superficial mucosa, and one was a T1b tumor. In other words, the technique rarely misses clinically significant disease, but very shallow lesions can escape detection, a limitation the authors acknowledge openly. Among the 104 men and 46 women enrolled, whose mean age was 60.5 years, the vast majority of tumors were amenable to layer-by-layer analysis.

The heart of the study lies in its quantitative approach to the five layers. Rather than simply eyeballing whether a layer looked interrupted, the ultrasonographers measured the thickness of each layer at the tumor site and compared it with the thickness of the same layer in adjacent normal wall, yielding a thickness difference for each band. Receiver operating characteristic analysis in the training set then identified cutoff values that separated one T stage from the next. The submucosa, layer L3, proved to be the pivotal structure. A difference in L3 thickness of 0.11 centimeters separated T1a from T1b tumors with an area under the curve of 0.957, while a cutoff of 0.23 centimeters distinguished T1b from T2 with an area under the curve of 0.910. These are strikingly high discriminative values for a bedside imaging measurement.

The algorithm then proceeds stepwise down the wall. When the L3 measurement places a tumor in the T2 range, a difference in L4 thickness, the muscularis propria, of 0.24 centimeters or more, with an area under the curve of 0.860, signals progression to T3. Interruption of the L3 layer itself, meaning a visible break in the submucosal echo band, narrows the diagnostic range to T2 or T3, excluding earlier stages. Finally, protrusion of the tumor beyond the serosal line, layer L5, by more than 0.50 centimeters identifies T4 disease, where the cancer has grown through the stomach wall, with an area under the curve of 0.980. Assembled into a diagnostic flowchart, these four objective indicators allow any trained ultrasonographer to walk from measurement to stage in a reproducible sequence, rather than relying on gestalt.

Validation results were competitive. In the combined analysis, the flowchart achieved 78.4 percent overall T-staging accuracy, and 76.5 percent in the independent testing set. Contrast-enhanced CT, performed on the same patients, managed only 66.4 percent, a difference that was statistically significant. The advantage was concentrated precisely where it matters most clinically: early gastric cancer. For distinguishing T1a from T1b disease, OCTU reached 65.2 percent accuracy against 39.1 percent for CT, and for separating T1 from T2 tumors it scored 72.0 percent versus 48.0 percent, both differences significant. For advanced tumors, T3 and T4, the two modalities performed comparably. Because the choice between endoscopic resection and major surgery hinges on whether an early tumor has reached the submucosa, this superiority in early-stage discrimination carries direct surgical consequences.

The comparison with endoscopic ultrasonography, the current reference standard for depth assessment, is an important context for these numbers. EUS places a high-frequency transducer directly inside the stomach and offers excellent layer resolution, but it is invasive, operator-dependent, expensive, and unavailable in many centers, particularly in regions where gastric cancer is most prevalent. OCTU, by contrast, requires only a standard ultrasound machine, an oral contrast agent, and a trained sonographer. It involves no ionizing radiation, no sedation, and no endoscopic instrumentation. A validated, standardized OCTU protocol could therefore extend accurate depth staging to hospitals that will never have the endoscopic ultrasound volume to develop expertise, and could serve as a rapid triage tool even in well-equipped centers.

The study’s limitations are those of a single-center design. All patients were imaged at one high-volume cancer hospital in Beijing by sonographers embedded in a specialized oncology practice, and the testing set of 34 patients, while adequate for validation, is modest. Whether the reported cutoffs of 0.11, 0.23, 0.24, and 0.50 centimeters transfer unchanged to other machines, other contrast agents, and less specialized operators will require multicenter confirmation. The six missed early tumors also mean OCTU cannot stand entirely alone; endoscopy remains indispensable for detecting and characterizing the primary lesion. What the study demonstrates is that, once a tumor is identified, its depth can be staged objectively and reproducibly from the body surface.

Still, the implications are considerable. Gastr cancer incidence remains high across East Asia and rising in many other regions, and every patient with resectable disease faces a staging pathway that shapes treatment. A technique that is cheaper than CT, safer than repeated radiation exposure, more accurate than CT for the early stages that determine surgical strategy, and now supported by an explicit, measurement-based flowchart rather than subjective reading, represents a meaningful shift in what routine preoperative assessment can look like. The Beijing team’s work, funded by the Beijing Natural Science Foundation, provides the kind of prospectively validated, threshold-driven protocol that imaging guidelines demand, and it arrives with a clear roadmap: multicenter trials to confirm generalizability, and integration of OCTU into staging algorithms alongside endoscopy and CT. If those steps succeed, the humble ultrasound probe, armed with a swallow of oral contrast and a set of millimeter-scale cutoffs, may become a standard first stop in deciding how a stomach cancer is treated.

Subject of Research: Preoperative T-staging of gastric cancer using oral contrast-enhanced transabdominal ultrasound

Article Title: Preoperative T-staging flowchart using oral contrast-enhanced transabdominal ultrasound for gastric cancer: single-center prospective study

Article References: Liu, Y.-H., Tang, H.-W., Wu, A.-W., Shan, F., Li, S., Yan, K., & Dai, Y. (2026). Preoperative T-staging flowchart using oral contrast-enhanced transabdominal ultrasound for gastric cancer: single-center prospective study. BMC Cancer. https://doi.org/10.1186/s12885-026-17016-9

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17016-9

Keywords: gastric cancer, T staging, oral contrast-enhanced ultrasound, transabdominal ultrasound, contrast-enhanced CT, cancer imaging, neoplasm staging, gastric wall layers, prospective study, diagnostic flowchart, early gastric cancer, Peking University Cancer Hospital

The investigative team began with a clinically grounded question: which genetic alterations predict failure of immunotherapy in gastric cancer? To answer it, they performed whole-exome sequencing on tumor specimens from patients who had received neoadjuvant chemotherapy combined with PD-1 blockade, the current backbone of perioperative treatment for many locally advanced cases. Among the recurrently mutated genes associated with poor treatment outcome, KRAS emerged as a standout. The signal was particularly striking because it persisted even in tumors that carried the two established biomarkers used to select patients for immune checkpoint inhibitors: mismatch repair deficiency, known as dMMR status, and a combined positive score, or CPS, above ten. Patients whose tumors harbored both favorable biomarkers and a KRAS mutation nonetheless derived very limited benefit, a finding that challenges the assumption that biomarker-positive gastric cancers respond uniformly to immunotherapy.

Multiplex immunohistochemistry on patient samples added a spatial dimension to the genetic data. KRAS-mutant gastric tumors proved to be poorly infiltrated by lymphocytes, and the deficit was most pronounced among intratumoral CD8-positive T cells, the cytotoxic warriors that checkpoint inhibitors are designed to unleash. In their place, the tumors showed increased infiltration of CD68-positive myeloid cells, a population frequently associated with pro-tumor inflammation and immune suppression. The picture that emerged was of a tumor microenvironment stripped of its anti-cancer firepower and stocked instead with cells that dampen immune attack, a configuration that would predict resistance to PD-1-directed therapy regardless of biomarker status.

To move from correlation to causation, the researchers needed a model that faithfully reproduced both the genetics and the immunology of human disease. They generated a stomach-specific, genetically faithful and immunocompetent mouse model of KRASG12D-driven gastric adenocarcinoma, designated the CPPK model, built on Anxa10-CreERT2, KrasG12D and Trp53-floxed alleles. Because the model develops in animals with intact immune systems, it captures the full interplay between oncogenic signaling and the immune microenvironment, something conventional cell-line xenografts cannot do. The model recapitulated the stepwise development of human poorly differentiated gastric adenocarcinoma with remarkable fidelity, progressing from early antralization of gastric glands to advanced tubular and intestinal-type adenocarcinoma, and ultimately to liver and peritoneal metastasis. Mirroring the clinical observations, CPPK mice were intrinsically resistant to PD-1 blockade, providing a platform in which the biology of resistance could be dissected and therapeutic combinations tested.

Single-cell RNA sequencing of tumor tissues from the model exposed the architecture of immune suppression in unprecedented detail. Regulatory T cells, the immunosuppressive subset that normally keeps immune responses in check, comprised 41.7 percent of all tumor-infiltrating T cells, an extraordinary proportion that dwarfs what is seen in immunologically hot tumors. Within the NKT cell compartment, 55.3 percent of cells displayed an exhausted phenotype, functionally crippled by chronic antigen stimulation. Perhaps most tellingly, TGF-beta signaling was markedly activated in the tumor Tregs, and spatial analysis revealed that this pathway co-localized with the CTLA-4 molecule within the same cells. Together, these data identified TGF-beta-positive regulatory T cells as the central hub maintaining immune suppression, and they pointed to CTLA-4 as the molecular handle by which those cells might be targeted.

The therapeutic arm of the study tested MRTX1133, a recently developed small-molecule inhibitor of KRASG12D, in the mouse model. The drug effectively suppressed tumor growth and prolonged survival, and it inhibited KRASG12D gastric cancer cell lines and organoids with half-maximal inhibitory concentrations ranging from 271 to 485 nanomolar. On its face, this seemed like a victory for precision oncology. Yet functional immune analyses told a more sobering story: effective antitumor immunity was not restored by KRAS inhibition alone. The immune cells expanding after treatment were predominantly immunosuppressive Tregs rather than cytotoxic lymphocytes, and the function of cytotoxic T cells remained essentially unchanged. Mechanistically, TGF-beta signaling proved necessary to maintain Treg dominance and suppress effector T cell function, meaning that removing the oncogenic driver did not, by itself, dismantle the immunosuppressive apparatus the tumor had built.

This insight set up the study’s central therapeutic experiment. Because CTLA-4 blockade is known to act directly on regulatory T cells, depleting or disabling them within tumors, the researchers combined KRAS inhibition with an anti-CTLA-4 antibody. The combination markedly attenuated TGF-beta activity, impaired Treg function and synergistically enhanced antitumor immune responses. In other words, the targeted therapy shrank the tumor and the immunotherapy removed the suppressive cells that had been shielding it, addressing two halves of the same problem simultaneously. The doublet transformed an immunologically cold, Treg-dominated tumor into one in which effector immunity could operate.

The most dramatic results came when a third agent was layered on. Adding PD-1 blockade to the KRAS-CTLA-4 doublet led to complete eradication of three subcutaneous tumors in the preclinical models, and the combination significantly prolonged survival in the spontaneous CPPK model, where tumors arise in their native anatomical location and metastasize naturally. These findings identify oncogenic KRAS as a key regulator of TGF-beta-dependent immune suppression in gastric adenocarcinoma and provide a strong preclinical rationale for CTLA-4-based combination immunotherapy in this molecularly defined subset of patients. For a cancer subtype in which even biomarker-positive cases fail PD-1 therapy, the prospect of a rational triple combination is significant.

Beyond its immediate therapeutic implications, the study carries broader lessons for the field of cancer immunology. It demonstrates that oncogene addiction and immune evasion are not parallel phenomena but deeply intertwined ones, with mutant KRAS actively recruiting and maintaining a regulatory T cell niche through TGF-beta. It also illustrates why single-agent approaches so often disappoint: dismantling the driver does not automatically dismantle the microenvironment the driver created. The work underscores the value of genetically faithful, immunocompetent models for dissecting such interactions, and it suggests that biomarker-guided immunotherapy strategies should account for oncogenic drivers like KRAS even when canonical predictive markers appear favorable.

Clinical translation will require careful evaluation, as the findings remain preclinical and the safety of combining KRAS inhibitors with dual checkpoint blockade in patients with gastric cancer has yet to be established. Nevertheless, the study, carried out by researchers from Peking University Cancer Hospital & Institute and collaborating institutions and supported by grants from the National Science and Technology Major Project of China, the Beijing Natural Science Foundation and the National Natural Science Foundation of China, charts a clear path forward. For the roughly one in ten patients with gastric adenocarcinoma whose tumors harbor KRAS mutations, a group currently left behind by the immunotherapy revolution, the combination of KRAS inhibition with CTLA-4 blockade offers something they have not had before: a biologically grounded reason for hope.

Subject of Research: KRAS-mutant gastric adenocarcinoma and combination immunotherapy targeting the TGF-beta-dependent regulatory T cell microenvironment

Article Title: KRAS inhibition combined with CTLA-4 blockade overcomes immunotherapy resistance in KRAS-mutant gastric cancer

Article References: KRAS inhibition combined with CTLA-4 blockade overcomes immunotherapy resistance in KRAS-mutant gastric cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: KRAS, gastric adenocarcinoma, CTLA-4, PD-1, TGF-beta, regulatory T cells, immunotherapy resistance, MRTX1133, tumor microenvironment, single-cell RNA sequencing, immune checkpoint inhibitors, Peking University Cancer Hospital

The study, published in Cancer Immunology, Immunotherapy, evaluated sintilimab, a monoclonal antibody that blocks the programmed cell death protein 1, or PD-1, a molecular brake that tumors exploit to disable attacking immune cells. By releasing this brake, PD-1 inhibitors allow T cells to recognize and destroy cancer cells that would otherwise hide in plain sight. Sintilimab has already transformed the treatment landscape for several cancers in China, but its role in the post-surgical setting for esophageal cancer had remained largely uncharted territory.

The clinical problem the researchers tackled is a genuine one. While neoadjuvant therapy followed by esophagectomy has become a standard approach for locally advanced esophageal squamous cell carcinoma, many patients still harbor residual pathological disease after treatment, and others undergo upfront surgery only to be found with high-risk features such as deep tumor invasion or lymph node involvement. For these patients, evidence to guide adjuvant immunotherapy has been sparse. Most of the landmark immunotherapy trials in esophageal cancer focused on advanced, metastatic disease or on the neoadjuvant window before surgery, leaving the post-operative period as a therapeutic blind spot.

The trial, registered as ChiCTR2100049784, enrolled 32 patients between August 2021 and July 2023 at a single center. All had undergone R0 resection, meaning surgeons had removed the tumor with microscopically clear margins, the best achievable surgical outcome. Yet every patient carried high-risk pathology: either ypT1-4a and/or ypN+ disease after neoadjuvant therapy, or pT3-4 and/or pN+ disease after surgery performed first without pre-treatment. The majority, 27 patients or 84.4 percent, had received neoadjuvant therapy combining a PD-1 inhibitor with chemotherapy before their operation. Two patients, 6.3 percent, had neoadjuvant chemotherapy alone, and three patients, 9.4 percent, had undergone upfront surgery.

The treatment regimen was straightforward but demanding. Patients received sintilimab monotherapy every three weeks for up to 12 months, corresponding to 17 planned cycles. No chemotherapy or radiation was layered on top; the immunotherapy stood alone. The primary endpoint was the one-year recurrence-free survival rate, a prespecified benchmark the study needed to meet to be considered a success. Secondary endpoints included overall survival and safety, assessed throughout the treatment period and beyond.

The results exceeded expectations for a trial of this size. At a median follow-up of 47.0 months, nearly four years, the median recurrence-free survival had not been reached, meaning more than half of the patients had not experienced a recurrence by the time of analysis. The one-year recurrence-free survival rate stood at 87.5 percent, comfortably meeting the prespecified primary endpoint, while the two-year rate was 65.6 percent. Overall survival followed a similarly favorable trajectory: 93.8 percent of patients were alive at one year and 78.1 percent at two years, with median overall survival likewise not reached.

Safety data provided reassurance that the approach is tolerable. Treatment-related adverse events occurred in 13 patients, or 40.6 percent of the cohort, and grade 3 or higher events, the serious toxicities that can threaten organ function or require hospitalization, appeared in 7 patients, or 21.9 percent. Critically, no treatment-related deaths occurred, a notable finding given that immune checkpoint inhibitors can occasionally trigger severe immune-mediated inflammation in organs such as the lungs, liver, colon, or endocrine glands. Despite the manageable safety profile, adherence to the full course was imperfect: 17 patients, or 53.1 percent, completed all 17 planned cycles, a completion rate that reflects the real-world challenges of maintaining a year-long treatment, whether due to adverse events, recurrence, or patient choice.

The immunological rationale underlying these findings deserves attention. Neoadjuvant chemoradiation or chemoimmunotherapy can prime the immune system by releasing tumor antigens as cancer cells die, creating a window of heightened immune surveillance. Administering a PD-1 inhibitor in the adjuvant setting may then consolidate that priming, helping circulating and tissue-resident T cells eliminate microscopic residual disease before it can establish clinically detectable metastases. The strong showing of the 87.5 percent one-year recurrence-free survival rate in a cohort overwhelmingly composed of patients treated with neoadjuvant PD-1 blockade plus chemotherapy suggests that the perioperative sequencing of immunotherapy, before and after surgery, may act synergistically, though the single-arm design cannot formally disentangle the contributions of each component.

The authors and independent observers alike caution that the study’s design imposes limits on interpretation. With no control arm, it is impossible to say with certainty how patients would have fared with observation alone or with alternative adjuvant strategies, and the single-center enrollment of 32 patients means the confidence intervals around the survival estimates are wide. Selection factors, including the general fitness required to undergo esophagectomy and then a year of immunotherapy, may also inflate outcomes relative to the broader population of high-risk patients. The researchers themselves state that the findings support further evaluation in larger randomized controlled trials with longer follow-up, and the field is watching ongoing perioperative immunotherapy studies in esophageal cancer that may soon provide the randomized evidence needed to change guidelines.

Even with those caveats, the trial adds an important piece to a rapidly evolving puzzle. Esophageal squamous cell carcinoma remains one of the most lethal malignancies worldwide, with five-year survival historically languishing in the double digits even after curative-intent surgery. The demonstration that adjuvant sintilimab monotherapy met its prespecified efficacy endpoint with manageable toxicity and no treatment-related deaths provides a template for how post-operative immunotherapy could be integrated into multimodal treatment programs. If larger randomized trials confirm these results, the standard of care for high-risk resected esophageal cancer could shift from watchful waiting after surgery to a full perioperative immunotherapy strategy, turning a period of anxious uncertainty into an active, immune-based defense against recurrence.

Subject of Research: Adjuvant PD-1 inhibitor therapy for high-risk resected esophageal squamous cell carcinoma

Article Title: Efficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trial

Article References: Efficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trial. (n.d.). https://doi.org/10.1007/s00262-026-04579-6

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04579-6

Keywords: esophageal squamous cell carcinoma, sintilimab, PD-1 inhibitor, adjuvant immunotherapy, recurrence-free survival, phase II trial, esophagectomy, cancer immunotherapy, neoadjuvant therapy, overall survival, treatment-related adverse events, Peking University Cancer Hospital